Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors (FACPT)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess short and long term outcomes after radiofrequency ablation (RFA) combined with chemotherapy for pulmonary malignancies in patients who are not candidates for surgical resection. This study will evaluate the efficacy of RFA combined with chemotherapy for the treatment of lung tumors by assessing its impact on local tumor control, progression free survival, overall survival, dyspnea score and quality of life (QOL).
| Condition | Intervention |
|---|---|
|
NSCLC Pulmonary Metastases |
Procedure: Radiofrequency Ablation |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | A Prospective Study of Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors |
- Progression-free survival [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Overall survival [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 48 |
| Study Start Date: | November 2009 |
| Estimated Study Completion Date: | June 2011 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| Radiofrequency Ablation |
Procedure: Radiofrequency Ablation
Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
Other Name: WHK-3 RFA (Welfare Electronics Co., Beijing PR China)
|
Detailed Description:
Percutaneous image-guided RFA is a minimally invasive technique used to treat solid tumours. Because of its ability to produce large volumes of coagulation necrosis in a controlled fashion, this technique has gained acceptance as a viable therapeutic option for unresectable liver malignancies. Recently, RFA has been proposed as a viable option for the treatment of pulmonary malignancies. Experimental studies in animal tumor models have confirmed the effectiveness of RFA in the destruction of experimentally-induced pulmonary malignancies. Pilot clinical investigations have suggested that the treatment can achieve high proportions of tumor response. We designed a prospective clinical trial aimed at assessing feasibility, safety and effectiveness of RFA combined with chemotherapy in the treatment of lung malignancies.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients with pulmonary malignancies are not candidates for surgical resectionpatients.
Inclusion Criteria:
- adult (> 18 years) male or female patient
- patient has biopsy-proven NSCLC or lung metastasis
- patient has been rejected for surgery and has been considered unfit for radiation therapy
- each 6 cm or smaller in greatest diameter of tumor, by CT scan
- tumors are located at least 1 cm from trachea; main bronchi; esophagus; aorta; aortic arch branches; pulmonary artery; and heart
- tumors are accessible by percutaneous route
- patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- patient has platelet count > 100 x 109 /L and international normalized ratio ≤ 1.5
- patient has signed written informed consent prior to any study specific procedures.
Exclusion Criteria:
- patient is considered at high-risk for RF ablation due to major co-morbid medical conditions
- patient has more than 3 tumors / lung
- patient has at least one tumor > 6 cm in greatest diameter
- tumor is associated with atelectasis or obstructive pneumonitis
- patient has renal failure requiring hemodialysis or peritoneal dialysis
- patient has active clinically serious infection
- patient has history of organ allograft
- patient has history of substance abuse or any medical, psychological or social conditions that may interfere with his / her participation in the study or evaluation of the study results
- patient is pregnant or breast-feeding
- patient has ECOG performance status > 2
- patient has platelet count ≤ 100 x 109 /L or international normalized ratio > 1.5.
Contacts and Locations| Contact: Weiqiang Yin, MD | +86-20-833 37792 | dryin2010@gmail.com |
| Contact: Daoyuan Wang, MD | +86-20-833 37792 | ghealth2008@gmail.com |
| China, Guangdong | |
| Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College | Recruiting |
| Guangzhou, Guangdong, China, 510120 | |
| Contact: Jianxing He, MD, FACS +86-20-83337792 drjianxing.he@gmail.com | |
| Contact: Xin Xu, MD +86-20-83337792 yichunrenjia@126.com | |
| Principal Investigator: Jianxing He, MD, FACS | |
| Principal Investigator: | Jianxing He, MD, FACS | Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College |
More Information
No publications provided
| Responsible Party: | The First Affiliated Hospital of Guangzhou Medical College, Guangzhou Medical College |
| ClinicalTrials.gov Identifier: | NCT01105182 History of Changes |
| Other Study ID Numbers: | FAHG20100201 |
| Study First Received: | April 12, 2010 |
| Last Updated: | April 15, 2010 |
| Health Authority: | China: Food and Drug Administration |
Keywords provided by The First Affiliated Hospital of Guangzhou Medical University:
|
Radiofrequency Ablation |
Additional relevant MeSH terms:
|
Neoplasm Metastasis Lung Neoplasms Neoplastic Processes Neoplasms Pathologic Processes |
Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on June 13, 2013